Fondaparinux (Arixtra)

Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.

Also Known As:

Arixtra; Fondaparinux Sodium; Quixidar; (2S,3S,4R,5R,6R)-6-((2R,3R,4R,5R,6R)-6-((2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-(sulfooxymethyl)oxan-3-yl)oxy-5-sulfooxyoxan-3-yl)oxy-5-(sulfoamino)-4-sulfooxy-2-(sulfooxymethyl)oxan-3-yl)oxy-3-((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-(sulfooxymethyl)oxan-2-yl)oxy-4,5-dihydroxyoxane-2-carboxylic acid

Networked: 928 relevant articles (101 outcomes, 216 trials/studies)

Relationship Network

Drug Context: Research Results

Carbohydrates: 22023
- Polysaccharides: 15383
  - Oligosaccharides: 3566
    - Fondaparinux: 928

Experts

1.	Warkentin, Theodore E: 20 articles (01/2020 - 06/2002)
2.	Turpie, Alexander G G: 19 articles (07/2017 - 01/2002)
3.	Mehta, Shamir R: 17 articles (04/2015 - 03/2005)
4.	Yusuf, Salim: 17 articles (05/2014 - 03/2005)
5.	Bauer, Kenneth A: 17 articles (09/2008 - 01/2002)
6.	Akl, Elie A: 15 articles (12/2021 - 05/2008)
7.	Afzal, Rizwan: 15 articles (05/2014 - 03/2005)
8.	Bassand, Jean-Pierre: 15 articles (02/2010 - 03/2005)
9.	Chrolavicius, Susan: 14 articles (12/2010 - 12/2005)
10.	Barba, Maddalena: 13 articles (12/2021 - 05/2008)

Related Diseases

1.	Venous Thromboembolism 01/01/2004 - "The further randomized, double-blind PENTHIFRA-PLUS trial showed that extending fondaparinux prophylaxis from one to four weeks after hip fracture surgery was well tolerated and, compared to one-week fondaparinux, dramatically reduced delayed venous thromboembolism events from 35.0% to 1.4% (p<0.001). " 01/01/2008 - "In a well designed trial (ARTEMIS) in acute medical patients aged > or = 60 years, fondaparinux was significantly more effective than placebo in terms of reducing the incidence of venous thromboembolism (VTE) up to day 15. " 07/01/2004 - "In patients undergoing elective hip replacement surgery, fondaparinux significantly reduced the frequency of venous thromboembolism (VTE). " 01/01/2019 - "Conclusions Fondaparinux was associated with a superior efficacy in terms of reduction of venous thromboembolism in this meta-analysis. " 11/01/2012 - "Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study."
2.	Hemorrhage 04/30/2013 - "In one large, placebo-controlled RCT of about 3000 patients, subcutaneous fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), ST extension (RR 0.08; 95% CI 0.03 to 0.22), and ST recurrence (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. " 03/14/2012 - "In a placebo-controlled RCT of about 3000 patients, fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), extension (RR 0.08; 95% CI 0.03 to 0.22), and recurrence of ST (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. " 12/01/2003 - "In a subgroup analysis of several large randomized trials, fondaparinux, 2.5 mg, begun < 6 h postoperatively was associated with increased major bleeding, without improved efficacy. " 05/01/2011 - "Even in the context of low access site complication rate provided by TRA, fondaparinux was effective in reducing major bleeding." 09/01/2004 - "This superior efficacy led to an overall increase in major bleeding, which was however primarily due to more fondaparinux-treated patients with bleeding indexes of 2 or greater. "
3.	Thrombosis (Thrombus) 10/01/2017 - "Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients." 09/23/2010 - "Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects. " 03/21/2014 - "Given the development of new thromboses in 3 of 8 patients, concern exists about the efficacy of fondaparinux in this patient population. " 03/01/2012 - "In vitro studies support the effectiveness of fondaparinux in preventing thrombus formation on mechanical heart valves. " 04/01/2011 - "Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study."
4.	Acute Coronary Syndrome 04/01/2010 - "Fondaparinux sodium injection has been accepted for priority review by the United States Food and Drug Administration based on positive results from two pivotal, Phase III trials (OASIS 5 and 6) that evaluated its role in the treatment of a broad spectrum of patients with acute coronary syndromes (ACS). " 11/01/2005 - "Finally, a number of Phase II trials investigated the safety and efficacy of fondaparinux in patients with acute coronary syndromes, and a large Phase III program is ongoing in this setting. " 01/01/2006 - "Fondaparinux in acute coronary syndromes: improved efficacy and safety." 03/01/2022 - "Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population." 09/22/2010 - "Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010. "
5.	Venous Thrombosis (Deep-Vein Thrombosis) 07/01/2005 - "In conclusion, due to its superior efficacy and satisfactory safety, fondaparinux may substantially improve the prevention and treatment of venous thrombosis." 01/01/2002 - "This superior efficacy of fondaparinux was also demonstrated for proximal deep vein thrombosis with a reduction of 57.4%. " 01/01/2004 - "Fondaparinux recipients had a lower incidence of proximal deep vein thrombosis (DVT) in two studies. " 10/01/2020 - "During fondaparinux treatment, platelet count did not increase and a lower leg deep vein thrombosis occurred. " 05/01/2016 - "Anti-Xa assays are useful for monitoring the effects of selective anti-Xa drugs, such as fondaparinux, in the prophylaxis of deep vein thrombosis. "

Related Drugs and Biologics

1.	Enoxaparin (Lovenox)
2.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
3.	Heparin (Liquaemin)
4.	Anticoagulants
5.	Factor Xa Inhibitors
6.	bivalirudin (Angiomax)
7.	Antithrombins
8.	Vitamin K
9.	Rivaroxaban
10.	edoxaban

Related Therapies and Procedures

1.	Orthopedic Procedures
2.	Therapeutics
3.	Percutaneous Coronary Intervention
4.	Catheters
5.	Hip Replacement Arthroplasty (Total Hip Replacement)